CL2016002338A1 - Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática . - Google Patents

Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .

Info

Publication number
CL2016002338A1
CL2016002338A1 CL2016002338A CL2016002338A CL2016002338A1 CL 2016002338 A1 CL2016002338 A1 CL 2016002338A1 CL 2016002338 A CL2016002338 A CL 2016002338A CL 2016002338 A CL2016002338 A CL 2016002338A CL 2016002338 A1 CL2016002338 A1 CL 2016002338A1
Authority
CL
Chile
Prior art keywords
compound
treatment
trifluoromethylphenoxypropyl
thio
ethoxy
Prior art date
Application number
CL2016002338A
Other languages
English (en)
Inventor
Pol Boudes
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of CL2016002338A1 publication Critical patent/CL2016002338A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

SE DESCRIBE EL USO DE UN COMPUESTO QUE ES ÁCIDO R-2-4-2-ETOXI-3-4-TRIFLUOROMETILFENOXIPROPIL-TIO-2-METILFENOXI ACÉTICO MBX-8025, PARA EL TRATAMIENTO DE UNA ENFERMEDAD COLESTÁSICA INTRAHEPÁTICA
CL2016002338A 2014-03-20 2016-09-15 Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática . CL2016002338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20

Publications (1)

Publication Number Publication Date
CL2016002338A1 true CL2016002338A1 (es) 2017-04-21

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002338A CL2016002338A1 (es) 2014-03-20 2016-09-15 Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .

Country Status (27)

Country Link
US (5) US9486428B2 (es)
EP (1) EP3119384B1 (es)
JP (1) JP6568577B2 (es)
KR (1) KR102000332B1 (es)
CN (1) CN106102734B (es)
AU (1) AU2015231232B2 (es)
BR (1) BR112016020260A8 (es)
CA (1) CA2941401C (es)
CL (1) CL2016002338A1 (es)
CY (1) CY1120927T1 (es)
DK (1) DK3119384T3 (es)
EA (1) EA032358B1 (es)
ES (1) ES2701094T3 (es)
HR (1) HRP20181914T1 (es)
HU (1) HUE041733T2 (es)
IL (1) IL247920B (es)
LT (1) LT3119384T (es)
MX (1) MX367478B (es)
NZ (1) NZ724057A (es)
PH (1) PH12016501769B1 (es)
PL (1) PL3119384T3 (es)
PT (1) PT3119384T (es)
RS (1) RS57970B1 (es)
SI (1) SI3119384T1 (es)
UA (1) UA120756C2 (es)
WO (1) WO2015143178A1 (es)
ZA (1) ZA201606043B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346498B1 (en) * 2008-10-17 2018-12-26 Cymabay Therapeutics, Inc. Methods of reducing small, dense ldl particles
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA125600C2 (uk) * 2017-09-26 2022-04-27 Сімабей Терапьютікс, Інк. Лікування холестатичного свербежу
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
IL304873A (en) 2021-02-01 2023-10-01 Cymabay Therapeutics Inc Treatment of cholangiopathy with saldalafar

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
DE602004022179D1 (de) 2003-09-19 2009-09-03 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP2346498B1 (en) 2008-10-17 2018-12-26 Cymabay Therapeutics, Inc. Methods of reducing small, dense ldl particles
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
EA201790091A1 (ru) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA125600C2 (uk) 2017-09-26 2022-04-27 Сімабей Терапьютікс, Інк. Лікування холестатичного свербежу
US20200155650A1 (en) 2018-11-16 2020-05-21 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
SI3119384T1 (sl) 2018-12-31
AU2015231232B2 (en) 2018-08-02
US9486428B2 (en) 2016-11-08
ES2701094T3 (es) 2019-02-20
RS57970B1 (sr) 2019-01-31
US20180036268A1 (en) 2018-02-08
PH12016501769A1 (en) 2017-01-09
IL247920B (en) 2019-03-31
PL3119384T3 (pl) 2019-03-29
US20210023031A1 (en) 2021-01-28
BR112016020260A8 (pt) 2021-06-29
CA2941401C (en) 2019-06-11
HRP20181914T1 (hr) 2019-01-11
DK3119384T3 (en) 2018-12-03
ZA201606043B (en) 2018-05-30
JP2017508817A (ja) 2017-03-30
US20170014363A1 (en) 2017-01-19
US10828273B2 (en) 2020-11-10
US9808436B2 (en) 2017-11-07
CN106102734B (zh) 2019-05-14
PH12016501769B1 (en) 2017-01-09
JP6568577B2 (ja) 2019-08-28
CN106102734A (zh) 2016-11-09
KR102000332B1 (ko) 2019-07-15
CY1120927T1 (el) 2019-12-11
CA2941401A1 (en) 2015-09-24
US20150265560A1 (en) 2015-09-24
US11406611B2 (en) 2022-08-09
EP3119384B1 (en) 2018-09-12
MX2016012203A (es) 2017-01-19
US20190192459A1 (en) 2019-06-27
WO2015143178A1 (en) 2015-09-24
NZ724057A (en) 2018-09-28
MX367478B (es) 2019-08-23
EP3119384A1 (en) 2017-01-25
EA201691887A1 (ru) 2017-03-31
EA032358B1 (ru) 2019-05-31
PT3119384T (pt) 2018-12-12
BR112016020260A2 (pt) 2017-08-15
LT3119384T (lt) 2018-11-26
AU2015231232A1 (en) 2016-09-22
UA120756C2 (uk) 2020-02-10
US10220011B2 (en) 2019-03-05
HUE041733T2 (hu) 2019-05-28
KR20160125424A (ko) 2016-10-31

Similar Documents

Publication Publication Date Title
CL2016002338A1 (es) Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática .
BR112017004209A2 (pt) derivados de tetrahidronaftaleno que inibem a proteína mcl-1.
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
DK3209656T3 (da) Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere
DK3977993T3 (da) Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament
BR112017007053A2 (pt) compostos neuroativos e métodos de utilização deste composto.
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
DK3194411T3 (da) Nukleotidanaloger
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
CL2015000430S1 (es) Alumbrado exterior.
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
CR20170005A (es) Derivados de insoindolina
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
DK3202766T3 (da) Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor
CO2019006234A2 (es) Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal
CL2017000151A1 (es) Derivados de piridona
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
DK3186227T3 (da) Nye sulfonylaminobenzamid-forbindelser som anthelmintika
DK3204357T3 (da) Fluorescerende, syntetiske retinoider
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.